- Home
- PHT vs TRDA Comparison
PHT vs TRDA Comparison
Compare PHT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- TRDA
- Stock Information
- Founded
- PHT 2002
- TRDA 2016
- Country
- PHT United States
- TRDA United States
- Employees
- PHT N/A
- TRDA N/A
- Industry
- PHT Investment Managers
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- PHT Finance
- TRDA Health Care
- Exchange
- PHT Nasdaq
- TRDA Nasdaq
- Market Cap
- PHT 244.7M
- TRDA 233.5M
- IPO Year
- PHT N/A
- TRDA 2021
- Fundamental
- Price
- PHT $8.32
- TRDA $5.47
- Analyst Decision
- PHT
- TRDA Strong Buy
- Analyst Count
- PHT 0
- TRDA 3
- Target Price
- PHT N/A
- TRDA $25.67
- AVG Volume (30 Days)
- PHT 85.5K
- TRDA 253.2K
- Earning Date
- PHT 01-01-0001
- TRDA 08-06-2025
- Dividend Yield
- PHT 8.76%
- TRDA N/A
- EPS Growth
- PHT N/A
- TRDA N/A
- EPS
- PHT 0.98
- TRDA N/A
- Revenue
- PHT N/A
- TRDA $79,476,000.00
- Revenue This Year
- PHT N/A
- TRDA N/A
- Revenue Next Year
- PHT N/A
- TRDA N/A
- P/E Ratio
- PHT $7.71
- TRDA N/A
- Revenue Growth
- PHT N/A
- TRDA N/A
- 52 Week Low
- PHT $6.41
- TRDA $4.93
- 52 Week High
- PHT $7.60
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- PHT 68.90
- TRDA 43.65
- Support Level
- PHT $8.28
- TRDA $5.46
- Resistance Level
- PHT $8.37
- TRDA $5.76
- Average True Range (ATR)
- PHT 0.04
- TRDA 0.30
- MACD
- PHT -0.00
- TRDA 0.06
- Stochastic Oscillator
- PHT 68.75
- TRDA 35.48
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.